{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-412300","form_type":"8-K","ticker":"BIOA","cik":"0001709941","company_name":"BioAge Labs, Inc.","filed_at":"2026-10-02T20:15:14+00:00","discovered_at":"2026-10-02T20:16:00.269138+00:00","generated_at":"2026-10-12T14:36:32.891215+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"BioAge Labs doses first patient in Phase 2 QUELL-DME trial of oral BGE-102 for DME","bullets":["First participant dosed in QUELL-DME, a randomized, controlled Phase 2 trial of once-daily oral BGE-102, an NLRP3 inhibitor, in adults with diabetic macular edema.","Approximately 180 participants randomized 1:1:1: anti-VEGF plus oral placebo; anti-VEGF plus BGE-102 90 mg daily; sham intravitreal injection plus BGE-102 90 mg daily.","12 weeks of once-daily dosing with a four-week follow-up; primary endpoint is change in best-corrected visual acuity at week 12, with retinal and biomarker exploratory endpoints.","Topline results expected in the second half of 2027, and are expected to inform development strategy in other NLRP3-driven retinal diseases including geographic atrophy."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-412300","json":"https://secwatch.observer/filing/0001193125-26-412300.json","markdown":"https://secwatch.observer/filing/0001193125-26-412300.md","text":"https://secwatch.observer/filing/0001193125-26-412300.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1709941/000119312526412300/0001193125-26-412300-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1709941/000119312526412300/bioa-20261002.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T14:36:32.891215+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}